###### Strengths and limitations of this study

-   This study is the first to use age-stratified and gender-stratified random samples of the Korean National Health Insurance claims database, which represents 98% of the South Korean population, to examine and compare medical use and costs associated with most frequent lumbar disorders.

-   National usage data on general management of most frequent lumbar disorders capture current clinical practice patterns, and surgery rates and diagnosis-related costs provide basic information for economic evaluation and health policy and budget appropriation.

-   Definition of lumbar disorders reliant on the disease classification system of the Korean National Health Insurance claims database may have limited accuracy despite being used as the grounds for reimbursements, and the authors therefore attempted to address potential selection bias by including lumbar radiographs as a selection criterion.

-   Although data were extracted from National Health Insurance claims statements that cover extensive information on healthcare interventions in a nationally representative sample, socioeconomic and clinical factors potentially influencing patterns of practice and non-reimbursable items and medicines could not be analysed.

Background {#s1}
==========

Low back pain (LBP) is a common condition which \>90% of American adults experience at least once in their lifetime,[@R1] and its treatment takes on significance as the most frequent cause of hospital visits, sick leave and absence from work.[@R2] Moreover, studies report increasing prevalence over the past several decades,[@R3] together with rise in costs.[@R4]

LBP is defined as localised pain between the 12th rib and gluteal folds with or without leg pain. Non-specific LBP (nLBP) is defined as back pain of unknown pathology. The greater majority of LBP cases are non-specific, with a specific cause identified in ∼5--10% of cases, which include intervertebral disc disorder (IDD) and spinal stenosis (SS).[@R5]

IDD is frequently associated with intervertebral disc degeneration and intervertebral disc herniation, affecting 10% of the population with low back and radiating pain over their lifetime.[@R6] A 2008 study using data from the Medical Expenditure Panel Survey reported that IDD was the largest specific diagnosis among patients with spinal disorder, accounting for almost 16% of the total patients.[@R7] Incidence of intervertebral disc herniation is highest in the 30--40 age range, and has been linked with dehydration and consequent degenerative disc change in this age group.[@R8] [@R9]

While it has been stated that there is no accurate diagnostic and/or classification criteria for SS,[@R10] it is still widely considered to refer to narrowing of the spinal canal and consequent nerve compression and ischaemia.[@R11] This mainly degenerative disorder is characterised by neurogenic claudication and is caused by various primary or secondary structural pathologies of the spine, intervertebral disc, facet joint and surrounding ligaments.[@R12] Prevalence of SS is increasing with marked growth of the ageing population over the past 20 years, and is especially prevalent in the 65+ age group.[@R13] Yearly SS incidence is estimated at 5 per 100 000 population,[@R14] and SS is the most common reason for spinal surgery in the elderly population aged 65 or older.[@R15]

These reports are in line with benefits by frequency of disease data from the 2013 Korean National Health Insurance Statistical Yearbook, in which spine-related Korean Standard Classification of Diseases (KCD) diagnoses with highest medical expense and number of patients were nLBP, IDD and SS. The number of patients with nLBP (KCD classification: dorsalgia, KCD code: M54) was 4568 435, with ∼579.1 billion KRW spent in annual medical expenses (seventh in overall disease diagnoses), number of patients with IDD (KCD classification: other IDDs, KCD code: M51) was 1847 234, with 587 billion KRW spent in medical expenses (sixth), and that of SS (KCD classification: other spondylopathies, KCD code: M48) was 1314 954, with a yearly medical expense of 468 billion KRW (ninth), showing that these three disorders incur considerable socioeconomic expense.[@R16]

Although medical expenditure and burden of disease of nLBP, IDD and SS are steadily increasing, reports on medical use and cost of each disease are scarce. Therefore, the objective of this study was to analyse billing data submitted to the Korean National Health Insurance and assessed by the Health Insurance Review and Assessment Service (HIRA) to compare medical care use and costs of most frequent lumbar disorders and thus provide basic information for future standards of the appropriate level of lumber disorder management in Korea.

Methods {#s2}
=======

Study population and sampling {#s2a}
-----------------------------

National Health Insurance billing data provided by HIRA include raw data of treatment prescriptions of all patients who received medical services over the course of 1 year after removal of identifying personal or corporate information.[@R17] This study used the 2011 HIRA National Patient Sample (NPS) data set, which includes 3% sample data of 2011 national insurance billing data (∼1.4 million patients) stratified by gender and 5-year age intervals.

National insurance billing statements contain charges to National Health Insurance and Medical Aid, and classify medical institutions into seven categories: upper level general hospitals, general hospitals, hospitals, clinics, Korean medicine hospitals, Korean medicine clinics and long-term care hospitals. Patients with lumbar disorder included for analysis were recategorised into three most frequent lumbar disorder groups, nLBP, IDD and SS, predefined as prefix codes M54, M51 and M48 through a literature review. Diagnoses were coded by the KCD, 6th revision (KCD-6) adapted from the International Classification of Diseases, 10th revision, and billing statements of patients aged \>120, those with missing cost data, those with 0 total cost, those with no record of lumbar X-ray, those with lumbar/spinal diagnoses unrelated to IDD or SS within the predefined prefix codes or those with lumbar/spinal diagnoses pertaining to non-lumbar regions were excluded. Claims information of 135 561 patients with lumbar disorder with the following prefix codes in primary or four secondary diagnoses were included for analysis through a panel discussion of four clinicians (one rehabilitation specialist and three Korean medicine rehabilitation specialists), and the flow chart of participant inclusion and exclusion is detailed in [figure 1](#BMJOPEN2016012432F1){ref-type="fig"}: M43, other deforming dorsopathies; M47, spondylosis; M48, other spondylopathies; M51, other IDDs; M54, dorsalgia; M99, biomechanical lesions, not elsewhere classified; and S33, dislocation, sprain and strain of joints and ligaments of lumbar spine and pelvis.

![Flow chart of inclusion and exclusion process of most frequent lumbar disorders. HIRA, Health Insurance Review and Assessment Service; IDD, intervertebral disc disorder; M43, other deforming dorsopathies; M47, spondylosis; M48, other spondylopathies; M51, other IDDs; M54, dorsalgia; M99, biomechanical lesions, not elsewhere classified; NPS, National Patient Sample; S33, dislocation, sprain and strain of joints and ligaments of the lumbar spine and pelvis; SS, spinal stenosis.](bmjopen2016012432f01){#BMJOPEN2016012432F1}

Of specific disease diagnoses, M541 (lumbar neuritis or radiculitis, not otherwise specified), initially classified as nLBP, was recategorised to the IDD group in accordance with a panel opinion with reference to clinical practice. Group classification of specific disease diagnoses is given in [table 1](#BMJOPEN2016012432TB1){ref-type="table"}. LBP-related diagnoses, injections, physiotherapy, surgical interventions and analgesics (opioid and non-opioid) were classified according to National Evidence-based healthcare Collaborating Agency reports.[@R18]

###### 

Group classification of specific disease diagnoses of nLBP, IDD and SS groups

  KCD-6 code\*   Disease diagnosis
  -------------- ---------------------------------------------------------------------------------------
  nLBP group     
   S33           Dislocation, sprain and strain of joints and ligaments of the lumbar spine and pelvis
   S335          Sprain and strain of the lumbar spine
   S336          Sprain and strain of the sacroiliac joint
   S337          Sprain and strain of other and unspecified parts of the lumbar spine and pelvis
   M544          Lumbago with sciatica
   M545          LBP
  IDD group      
   M541          Lumbar neuritis or radiculitis, not otherwise specified
   M51           Other IDDs
   M510          Lumbar disorders and other IDDs with myelopathy
   M511          Lumbar disorders and other IDDs with radiculopathy
   M512          Other specified intervertebral disc displacement
   M513          Other specified intervertebral disc degeneration, multiple sites in the spine
   M514          Schmorl\'s nodes
   M518          Other specified IDDs
   M519          IDD, unspecified
  SS group       
   M480          SS
   M993          Osseous stenosis of the neural canal
   M994          Connective tissue stenosis of the neural canal
   M995          Intervertebral disc stenosis of the neural canal
   M996          Osseous and subluxation stenosis of the intervertebral foramina
   M997          Connective tissue and disc stenosis of the intervertebral foramina

\*Diagnoses were coded by the KCD-6 which is the Korean version adapted from the International Classification of Diseases, 10th revision (ICD-10).

IDD, intervertebral disc disorder; KCD-6, Korean Standard Classification of Diseases, 6th revision; LBP, low back pain; nLBP, non-specific low back pain; SS, spinal stenosis.

National Health Insurance-related terms are defined as follows.[@R16]

Medical care institutions {#s2b}
-------------------------

Medical care institutions that treat and medicate patients include tertiary and general hospitals, hospitals, clinics, dental hospitals and clinics, midwifery clinics, admission facility-equipped health centres, health centres, health subcentres, primary healthcare centres, Korean medicine hospitals and clinics, and pharmacies. The term 'medical institution' is used to indicate medical care institutions with the exception of pharmacies.

Treatment amount {#s2c}
----------------

Treatment amount refers to the total medical care institution expenditure for patients who are covered by medical insurance, and comprises two kinds of costs: the amount paid by the insurer and that by the beneficiary. Generally speaking, it is the finalised total medical care cost adjusted and determined to be eligible for reimbursement through review by the HIRA from the initial non-adjusted estimate submitted by the medical care institution.

Benefit amount {#s2d}
--------------

The benefit amount is the reimbursement sum paid by the insurer (Korean National Health Insurance Service) to the medical care institution, and is determined by excluding the beneficiary-paid sum as decreed by law from the adjusted total treatment amount (or medication cost) determined to be valid through HIRA review.

Visit (admission) days {#s2e}
----------------------

The number of visits (in the outpatient department) or the length of hospital stay (in the inpatient department) of patient indicated in the submitted insurance claim statement is tallied.

Days of medication {#s2f}
------------------

Days of medication represent the total sum of visit days and in-care drug prescription days. Outpatient visits with drug prescription coinciding with hospitalisation and drug prescription on the same day were tallied as 1 day. Days of medication at the pharmacy indicate the number of days of receiving medication.

Statistical analysis {#s2g}
--------------------

Patient sociodemographic characteristics and frequency of prescriptions (surgical or medical interventions, including prescription medicine (analgesics)) are presented for each operational definition. The average treatment amount and benefit by group, and proportion of recipients of injection and non-injection treatment were also calculated, and descriptive statistics are presented by age and gender. All statistical analyses were performed using SAS 9.3 (SAS Institute., Cary, North Carolina, USA).

Results {#s3}
=======

While the 50--59 age range was most prevalent for the nLBP and IDD groups, prevalence increased with age in the SS group. All three groups showed a higher percentage of women than men. In use of medical institutions, clinics were most frequently visited in all three groups, followed by hospitals and general hospitals in the IDD and SS groups, and Korean medicine clinics in the nLBP group. In visits by medical specialty, visits to orthopaedics were most frequent in all three groups, followed by neurosurgery, and anaesthesiology and pain medicine specialists in the IDD and SS groups, and internal Korean medicine, and acupuncture and moxibustion specialists in the nLBP group. Visits to medical institutions located in Seoul were most common, followed by Gyeonggi-do, Busan and Gyeongsangnam-do ([table 2](#BMJOPEN2016012432TB2){ref-type="table"}).

###### 

Sociodemographic characteristics and medical care use by group\*

                                            nLBP      IDD    SS                       
  ----------------------------------------- --------- ------ -------- ------ -------- ------
  Age (years)                                                                         
   \<20                                     9069      8.0    884      1.8    53       0.2
   20--29                                   11 130    9.8    3406     6.9    270      0.9
   30--39                                   16 201    14.3   6513     13.2   771      2.6
   40--49                                   19 676    17.3   9207     18.7   2369     8.1
   50--59                                   22 984    20.2   11 942   24.3   6299     21.5
   60--69                                   17 646    15.5   9353     19.0   9061     30.9
   ≥70                                      16 927    14.9   7894     16.0   10 472   35.7
  Gender                                                                              
   Male                                     45 938    41.2   19 067   39.4   9828     34.1
   Female                                   65 606    58.8   29 346   60.6   19 014   65.9
  Treatment type used                                                                 
   Inpatient                                6142      5.3    6782     12.7   3163     10.2
   Outpatient                               109 305   94.7   46 669   87.3   27 975   89.8
  Public insurance scheme                                                             
   Health insurance                         105 613   94.4   45 458   93.4   26 262   90.1
   Medical aid                              6224      5.6    3034     6.2    2665     9.1
   Veteran healthcare                       98        0.1    165      0.3    230      0.8
  Medical institution visited                                                         
   Clinic                                   74 988    47.9   30 399   53.3   16 080   47.7
   Hospital                                 20 605    13.2   15 421   27.1   9179     27.2
   Korean medicine clinic                   41 295    26.4   2521     4.4    598      1.8
   General hospital                         10 345    6.6    5356     9.4    5377     16.0
   Upper level general hospital             2351      1.5    1689     3.0    1911     5.7
   Korean medicine hospital                 3471      2.2    1135     2.0    188      0.6
   Long-term care hospital                  1346      0.9    366      0.6    219      0.6
  Visits by medical specialty                                                         
   Orthopaedics                             72 196    41.6   29 682   49.0   20 082   56.9
   Neurosurgery                             13 685    7.9    14 375   23.7   7469     21.2
   Acupuncture and moxibustion medicine     23 883    13.8   1851     3.1    359      1.0
   Internal Korean medicine                 24 361    14.0   892      1.5    344      1.0
   Internal medicine                        9705      5.6    2112     3.5    1642     4.7
   Anaesthesiology and pain medicine        4795      2.8    3090     5.1    2356     6.7
   Surgery                                  6586      3.8    1574     2.6    704      2.0
   Other                                    18 359    10.6   7028     11.6   2324     6.6
  Location of medical institution visited                                             
   Seoul                                    23 836    19.8   11 283   22.0   6662     21.7
   Busan                                    7544      6.3    3654     7.1    2610     8.5
   Incheon                                  6320      5.3    2595     5.1    1037     3.4
   Daegu                                    5886      4.9    2498     4.9    1648     5.4
   Gwangju                                  4204      3.5    1684     3.3    857      2.8
   Daejeon                                  3818      3.2    1440     2.8    1160     3.8
   Ulsan                                    2355      2.0    940      1.8    495      1.6
   Gyeonggi-do                              25 289    21.1   10 967   21.4   4775     15.6
   Gangwon-do                               4013      3.3    1702     3.3    1181     3.9
   Chungcheongbuk-do                        4262      3.5    1773     3.5    1103     3.6
   Chungcheongnam-do                        5516      4.6    2147     4.2    1420     4.6
   Jeollabuk-do                             5567      4.6    2176     4.2    1807     5.9
   Jeollanam-do                             5627      4.7    2276     4.4    1659     5.4
   Gyeongsangbuk-do                         6693      5.6    2322     4.5    1882     6.1
   Gyeongsangnam-do                         7826      6.5    3147     6.1    1993     6.5
   Jeju-do                                  1344      1.1    680      1.3    365      1.2

\*Patients with overlapping records tallied as separate patients.

IDD, intervertebral disc disorder; nLBP, non-specific low back pain; SS, spinal stenosis.

The average treatment amount and the benefit per patient were 196 552 and 147 040 KRW in the nLBP group, 362 050 and 237 321 KRW in the IDD group, and highest in the SS group at 439 025 and 275 224 KRW, respectively. Women in the nLBP group spent more on medical expenses, but in the other two groups, men showed higher expenditure. While expenditure increased with age in the nLBP and SS groups, that of the IDD group peaked in patients in their 40s at 368 073 KRW. In expense by medical institution, long-term care hospitals had the highest expense in all three groups, followed by Korean medicine hospitals and upper level general hospitals. Analysis by medical specialty revealed that expense was highest in the anaesthesiology and pain medicine specialty in the nLBP group, and highest in the neurosurgery specialty in the IDD and SS groups. The average treatment amounts per patient in inpatient and outpatient care were highest in the SS group at 198 448 and 2 248 111 KRW, respectively. The average surgical treatment amount per patient was also highest in the SS group at 3 413 085 KRW ([table 3](#BMJOPEN2016012432TB3){ref-type="table"}).

###### 

Average treatment amount and benefit per patient by group\*

                                          nLBP        IDD         SS                                  
  --------------------------------------- ----------- ----------- ----------- ----------- ----------- -----------
  Gender                                                                                              
   Male                                   171 474     125 838     383 252     279 748     465 278     348 887
   Female                                 214 112     161 886     348 273     258 935     425 456     323 244
  Age (years)                                                                                         
   \<20                                   92 295      66 007      260 547     189 332     191 796     149 186
   20--29                                 130 363     91 517      299 123     211 662     152 432     104 315
   30--39                                 145 282     101 858     355 044     255 253     245 619     181 799
   40--49                                 173 030     124 379     368 073     269 164     346 966     258 196
   50--59                                 198 927     142 743     360 440     263 106     354 449     259 792
   60--69                                 229 733     175 831     354 971     263 339     462 022     347 040
   ≥70                                    310 271     254 221     374 094     291 192     494 715     382 559
  Treatment                                                                                           
   Inpatient                              937 692     722 549     1 343 232   1 045 275   2 248 111   1 791 462
   Outpatient                             147 888     109 451     180 379     125 214     198 448     139 719
  Treatment amount                                                                                    
   Total medical cost                     196 552                 362 050                 439 025     
   Self-payment cost                      49 122                  92 824                  101 551     
   Insurer-payment cost                   147 040                 267 132                 331 982     
  Public insurance scheme                                                                             
   Health insurance                       190 655     139 208     351 763     252 748     415 485     302 262
   Medical aid                            283 488     271 834     474 312     458 457     586 665     570 524
   Veteran healthcare                     245 792     74 441      596 402     316 720     814 934     506 786
  Medical institution                                                                                 
   Clinic                                 126 671     96 508      199 340     150 026     214 131     167 145
   Hospital                               152 812     109 882     444 272     327 561     422 746     315 882
   Korean medicine clinic                 136 645     106 555     128 753     99 095      168 161     133 518
   General hospital                       178 256     122 719     486 909     353 055     564 216     422 531
   Upper level general hospital           185 901     101 046     515 959     341 424     963 936     707 015
   Korean medicine hospital               249 263     178 340     536 411     386 986     432 867     314 565
   Long-term care hospital                294 487     223 931     541 724     435 586     1 232 065   990 993
  Medical specialty                                                                                   
   Orthopaedics                           131 039     97 302      252 103     187 903     339 495     259 354
   Neurosurgery                           118 663     82 131      453 336     333 135     509 032     379 142
   Acupuncture and moxibustion medicine   135 117     105 014     186 092     141 673     205 936     159 482
   Internal Korean medicine               124 159     96 030      165 971     127 618     184 338     148 624
   Internal medicine                      95 444      74 950      178 691     139 797     234 269     187 210
   Anaesthesiology and pain medicine      152 421     109 188     223 162     155 804     249 957     171 768
   Surgery                                134 784     103 408     219 405     170 091     226 691     177 391
  Surgery                                                                                             
   No                                     185 196     138 068     262 652     189 166     275 390     201 397
   Yes                                    1 320 929   1 040 705   2 194 448   1 719 504   3 413 085   2 721 099

\*Patients with overlapping records tallied as separate patients.

IDD, intervertebral disc disorder; nLBP, non-specific low back pain; SS, spinal stenosis.

Surgery rates were highest in the SS group at 0.9% for nLBP, 4.59% for IDD and 4.85% for SS. The most frequently used surgery code was open lumbar discectomy in the nLBP and IDD groups, and lumbar laminectomy closely followed by open lumbar discectomy in the SS group. The most frequent injection code for all three groups was epidural nerve block (lumbar and/or caudal), and in the IDD and SS groups, selective spinal nerve plexus, root or ganglion block and spinal nerve plexus, root or ganglion block (posterior division) followed.

Analgesics were used in 73.43% of the nLBP, 82.64% of the IDD and 86.46% of the SS group, and opioid analgesics were used in 4.12% of the IDD and 5.36% of the SS group. Of non-opioid analgesics, aceclofenac 100 mg was used most commonly in all three groups, followed by tramadol HCl 50 mg and talniflumate 370 mg. Of opioid analgesics, the nLBP and SS groups showed highest use in codeine phosphate 10 mg, while in the IDD group, pethidine HCl 50 mg was most commonly used, followed by codeine phosphate 10 mg. Deep heat therapy was most frequently prescribed as physiotherapy in all three groups, followed by superficial heat therapy and transcutaneous electrical nerve stimulation ([table 4](#BMJOPEN2016012432TB4){ref-type="table"}).

###### 

Use of surgery and injection procedures, physiotherapy and analgesics by group\*

                                                                                     Code       nLBP      IDD     SS                        
  ---------------------------------------------------------------------------------- ---------- --------- ------- -------- ------- -------- -------
  Total                                                                                         111 544   100.0   48 413   100.0   28 842   100.0
  Surgical intervention                                                                                                                     
   No                                                                                           111 194   99.69   48 178   99.51   28 641   99.30
   Yes                                                                                          1008      0.90    2221     4.59    1399     4.85
  Surgery procedure code                                                                                                                    
   Open lumbar discectomy                                                            N1493      6         0.01    1667     3.44    436      1.51
   Lumbar laminectomy                                                                N1499      4         0.00    121      0.25    451      1.56
   Lumbar arthrodesis (posterior technique)                                          N0469      --        --      25       0.05    103      0.36
   Endoscopic discectomy                                                             N1494      --        --      53       0.11    --       --
   Lumbar arthrodesis (anterior technique)                                           N0466      --        --      6        0.01    19       0.07
   Other                                                                                        1         0.00    10       0.02    5        0.02
  Non-surgical intervention                                                                                                                 
   Epidural nerve block (lumbar and/or caudal)                                       LA322      4480      4.02    6830     14.11   5202     18.04
   Spinal nerve plexus, root or ganglion block (posterior division)                  LA357      1149      1.03    740      1.53    494      1.71
   Selective spinal nerve plexus, root or ganglion block                             LA354      395       0.35    968      2.00    807      2.80
   Spinal nerve plexus, root or ganglion block (posterior medial branch)             LA358      588       0.53    862      1.78    629      2.18
   Spinal nerve plexus, root or ganglion block (facet joint)                         LA359      416       0.37    618      1.28    532      1.84
   Spinal nerve plexus, root or ganglion block (lumbar or sacral plexus)             LA253      419       0.38    447      0.92    340      1.18
   Spinal nerve plexus, root or ganglion block (dorsal root ganglion)                LA355      62        0.06    312      0.64    259      0.90
   Spinal nerve plexus, root or ganglion block (gray rami communicans)               LA356      1         0.00    3        0.01    2        0.01
  Physiotherapy                                                                                                                             
   Deep heat therapy                                                                 MM020      56 380    50.55   25 663   53.01   12 757   44.23
   Superficial heat therapy with deep heat therapy                                   MM015      56 078    50.27   25 512   52.70   12 651   43.86
   Transcutaneous electrical nerve stimulation with interferential current therapy   MM080      34 326    30.77   16 913   34.93   8228     28.53
   Transcutaneous electrical nerve stimulation                                       MM070      31 940    28.63   14 121   29.17   7141     24.76
   Superficial heat therapy                                                          MM010      13 001    11.66   7751     16.01   3730     12.93
   Intermittent pelvic traction therapy                                              MM052      4510      4.04    13 929   28.77   3095     10.73
   Rehabilitation low output laser therapy                                           MM085      5281      4.73    2885     5.96    1348     4.67
   Simple therapeutic exercise                                                       MM101      3673      3.29    2401     4.96    851      2.95
   Other                                                                                        1000      0.90    701      1.45    500      1.73
  Analgesics                                                                                                                                
   Non-opioid analgesics                                                                        81 150    72.75   38 014   78.52   23 391   81.10
   Opioid analgesics                                                                            761       0.68    1994     4.12    1545     5.36
  Non-opioid analgesics                                                                                                                     
   Aceclofenac 100 mg                                                                100901AT   25 102    22.50   14 044   29.01   8036     27.86
   Tramadol HCl 50 mg                                                                242303BI   24 344    21.82   9489     19.60   5919     20.52
   Talniflumate 370 mg                                                               234401AT   20 245    18.15   8378     17.31   3978     13.79
   Diclofenac sodium 75 mg                                                           143502BI   18 249    16.36   7065     14.59   3806     13.20
   Loxoprofen sodium 60 mg                                                           186101AT   18 589    16.67   6831     14.11   3288     11.40
   Acetaminophen 162.5 mg                                                            480600AT   9889      8.87    5609     11.59   4024     13.95
   Diclofenac-β-dimethyl-aminoethanol 90 mg                                          143601BI   8161      7.32    5242     10.83   3130     10.85
   Other                                                                                        48 265    43.27   24 452   50.51   17 699   61.37
  Opioid analgesics                                                                                                                         
   Codeine phosphate 10 mg                                                           313400AC   222       0.20    506      1.05    442      1.53
   Pethidine HCl 50 mg                                                               211501BI   181       0.16    574      1.19    266      0.92
   Pethidine HCl 25 mg                                                               211502BI   145       0.13    374      0.77    277      0.96
   Fentanyl citrate 100 mg                                                           158302BI   53        0.05    428      0.88    305      1.06
   Fentanyl 2.1 mg                                                                   158205CP   90        0.08    152      0.31    231      0.80
   Remifentanil HCl 1 mg                                                             457601BI   10        0.01    198      0.41    178      0.62
   Remifentanil HCl 2 mg                                                             457602BI   5         0.00    121      0.25    89       0.31
   Other                                                                                        202       0.18    385      0.80    554      1.92

\*Patients with overlapping records tallied as separate patients.

IDD, intervertebral disc disorder; nLBP, non-specific low back pain; SS, spinal stenosis.

A total 6876 (6.16%) of 111 544 patients with nLBP, 9546 (19.72%) of 48 413 patients with IDD and 7138 (24.75%) of 28 842 patients with SS received injection treatment. More women received injections compared to men in all three groups. In injections by age group, the proportion of recipients aged 60--69 was largest in the nLBP group, 50--59 in the IDD group and increased with age in the SS group. Surgery rates were higher in injection recipients than non-recipients in all groups with 1.0% in the nLBP, 7% in the IDD and 5.7% in the SS group, as was the average expenditure per patient in the injection compared to the non-injection subgroup in all three groups, at 407 083 in the nLBP, 615 312 in the IDD and 648 545 KRW in the SS group. While patients aged 70+ had highest medical expense by age in the injection and non-injection subgroups in the nLBP and SS groups, patients aged 30--39 showed highest average spending in the IDD group.

The average number of reimbursed days per injection patient was also higher than that for non-injection patients in all three groups at 15.4 days in the nLBP, 15.6 days in the IDD and highest at 16.5 days in the SS group. Similar to medical expense, patients aged 70+ spent most number of reimbursed days in medical care when categorised by age in the injection and non-injection subgroups in the nLBP and SS groups, and in patients aged 30--39 in the IDD group ([table 5](#BMJOPEN2016012432TB5){ref-type="table"}).

###### 

Comparison of patient characteristics in the injection and non-injection subgroups\*

                          N        Visit days per patient† (days)   Reimbursed visit days per patient‡ (days)   Benefit amount per patient§ (1000 KRW)   Treatment amount per patient¶ (1000 KRW)   Surgery rate (%)                                                                                                                     
  ----------------------- -------- -------------------------------- ------------------------------------------- ---------------------------------------- ------------------------------------------ ------------------ ------ ------ ------ ----------- ----------- ----------- --------- --------- --------- ------------ ------------- ------------
  Non-injection group     95 199   35 152                           18 769                                      7.2                                      7.5                                        7.8                7.9    9.4    12.0   131 670.4   216 818.0   278 164.9   177 044   294 237   366 803   888 (0.9%)   1354 (3.9%)   841 (4.5%)
  Injection group         6876     9546                             7138                                        14.1                                     12.5                                       12.4               15.4   15.6   16.5   303 823.8   452 656.1   486 879.6   407 083   615 312   648 545   69 (1.0%)    665 (7.0%)    409 (5.7%)
  *Non-injection group*                                                                                                                                                                                                                                                                                                                  
  Gender                                                                                                                                                                                                                                                                                                                                 
   Male                   40 083   14 020                           6527                                        6.0                                      7.3                                        7.5                6.7    10.1   15.5   114 337.4   230 789.5   301 476.3   156 465   316 138   400 303   448 (1.1)    727 (5.2)     340 (5.2)
   Female                 55 116   21 132                           12 242                                      8.0                                      7.6                                        7.9                8.7    8.9    10.1   144 275.8   207 548.6   265 736.1   192 010   279 706   348 943   440 (0.8)    627 (3)       501 (4.1)
  Age (years)                                                                                                                                                                                                                                                                                                                            
   \<20                   8933     788                              44                                          3.2                                      5.2                                        2.6                3.4    6.2    3.3    64 865.7    159 638.6   146 020.9   90 731    219 760   185 001   64 (0.7)     22 (2.8)      2 (4.6)
   20--29                 10 527   2860                             210                                         4.0                                      5.6                                        2.9                4.3    7.1    4.0    87 928.4    181 691.9   85 672.5    125 091   256 533   126 587   72 (0.7)     106 (3.7)     2 (1)
   30--39                 14 862   5266                             586                                         5.0                                      6.3                                        4.3                5.3    7.9    9.1    96 429.1    203 134.2   171 943.7   137 494   283 891   230 779   111 (0.7)    245 (4.7)     25 (4.3)
   40--49                 17 465   7160                             1708                                        6.0                                      7.0                                        5.2                6.4    8.7    7.0    117 771.5   222 320.8   223 097.5   163 727   303 530   299 184   148 (0.8)    314 (4.4)     79 (4.6)
   50--59                 19 208   8619                             4258                                        7.2                                      7.5                                        6.1                7.8    9.0    8.6    131 882.9   216 825.3   225 620.7   183 983   296 830   304 291   195 (1)      320 (3.7)     174 (4.1)
   60--69                 13 396   6093                             5727                                        9.5                                      8.2                                        7.9                10.7   10.9   13.8   157 362.1   202 838.8   291 869.0   205 801   273 636   390 158   135 (1)      191 (3.1)     275 (4.8)
   ≥70                    12 408   4867                             6473                                        13.3                                     9.4                                        9.7                15.3   11.8   13.9   233 606.0   248 595.8   321 709.3   284 758   316 882   413 017   163 (1.3)    156 (3.2)     284 (4.4)
  *Injection group*                                                                                                                                                                                                                                                                                                                      
  Gender                                                                                                                                                                                                                                                                                                                                 
   Male                   2535     3760                             2383                                        12.2                                     12.1                                       12.7               13.5   16.5   18.8   261 318.1   454 777.8   508 295.5   358 436   627 258   682 830   13 (0.5)     321 (8.5)     154 (6.5)
   Female                 4341     5786                             4755                                        15.2                                     12.7                                       12.3               16.5   15.1   15.3   328 645.7   451 277.4   476 146.9   435 491   607 549   631 362   56 (1.3)     344 (6)       255 (5.4)
  Age (years)                                                                                                                                                                                                                                                                                                                            
   \<20                   71       86                               6                                           7.2                                      11.7                                       4.3                7.5    16.0   5.5    174 687.2   444 109.2   244 083.3   242 313   610 245   329 338   0 (0)        6 (7)         0 (0)
   20--29                 341      473                              28                                          7.3                                      10.3                                       4.0                8.3    13.6   5.0    191 606.3   391 898.4   183 346.1   276 101   555 159   273 754   0 (0)        34 (7.2)      0 (0)
   30--39                 672      1033                             122                                         8.7                                      12.6                                       5.5                9.2    17.1   7.8    191 615.9   506 887.8   210 689.7   276 117   702 295   290 961   6 (0.9)      97 (9.4)      4 (3.3)
   40--49                 1018     1643                             445                                         9.6                                      12.2                                       8.8                10.1   15.1   11.1   219 955.0   464 857.9   392 506.9   310 927   638 448   534 569   4 (0.4)      138 (8.4)     19 (4.3)
   50--59                 1621     2507                             1391                                        11.8                                     12.1                                       9.3                12.7   14.4   11.7   267 612.6   421 782.8   376 752.8   372 247   580 843   525 597   14 (0.9)     154 (6.1)     67 (4.8)
   60--69                 1691     2155                             2356                                        15.4                                     12.2                                       12.1               17.1   15.8   16.5   317 361.9   443 174.7   489 538.3   422 422   599 557   651 039   12 (0.7)     158 (7.3)     137 (5.8)
   ≥70                    1684     1877                             2963                                        19.8                                     12.4                                       14.3               21.7   15.2   19.1   408 677.5   424 968.8   536 943.4   515 407   551 966   702 443   33 (2)       79 (4.2)      182 (6.1)

\*Patients with overlapping records tallied as one patient (overlapping not allowed).

†The number of outpatient visits or hospitalised days of patient indicated in the submitted insurance claim statement.

‡The number of reimbursed days includes the number of outpatient visits or hospitalised days and in-care drug prescription days. Outpatient visits or hospitalisation coinciding with drug prescription on the same day was tallied as 1 day.

§The amount of benefit paid by the insurer (Korean National Health Insurance Service) to the medical care institution, excluding self-payment cost paid by the beneficiary (patient), out of total treatment amount (or medication cost) determined to be valid through HIRA review.

¶The sum of self-payment cost paid by the beneficiary (patient) and benefit reimbursed by the insurer (Korean National Health Insurance Service) to the medical care institution. Total treatment amount of items determined to be eligible for reimbursement by the HIRA out of the treatment amount indicated in the submitted insurance claim statement.

HIRA, Health Insurance Review and Assessment Service; IDD, intervertebral disc disorder; LBP, low back pain; nLBP, non-specific low back pain; SS, spinal stenosis.

Discussion {#s4}
==========

This study used 2011 HIRA NPS data, which consist of 3% age-stratified and gender-stratified random samples that appropriately reflect the South Korean population of 2011 to capture real-world medical use and cost in most frequent lumbar disorders. This study is descriptive in nature, and reports sociodemographic characteristics, procedures, medication, average cost and benefits in most frequent lumbar disorders without addressing a specific hypothesis. Difference in current usage patterns were especially marked in the injection subgroup and the SS group.

The National Health Insurance claims database is representative of the population as it is a National Health Insurance scheme that covers ∼98% of the overall South Korean population. National Health Insurance was established in 1989 in South Korea and Employees\' Health Insurance was merged into the National Health Insurance service in 2000.[@R19] About 54% of medical expenditure is covered by the National Health Insurance service, and the remaining 46% is mostly paid through out-of-pocket expenses.[@R20]

Claims were filed to HIRA for 45.8 billion patients in 2011, which accounts for 90.3% of the total registered population of 50 billion. The total number of filed claims and total health expenditures have risen steadily, and as of 2011, the total number of filed claims reached 1.3 billion and with it, the total health expenditure ∼51.5 trillion KRW. The number of registered medical care institutions has also increased from 7289 in the 1980s to 82 948 in 2011.[@R21]

The National Health Insurance claims database covers all insurance billing codes submitted by registered medical care institutions to claim reimbursable medical costs from the National Health Insurance after HIRA review. Four different random sample data sets are available by year for 2009--2011: NPS, National Inpatient Sample, Aged Patient Sample and Paediatric Patient Sample. Claims statements cover extensive information on healthcare interventions (eg, treatment, procedures, diagnostic tests and prescription drugs), diagnosis, National Health Insurance-payment cost, beneficiaries\' self-payment cost, sociodemographic characteristics and medical institutions, and thus provide a useful source of nationwide epidemiological data of which the representativeness, reliability and validity have been confirmed.[@R19]

The large variations in diagnostic and therapeutic management of LBP and lumbar disorders among clinicians within and between countries,[@R22] coupled with the significant costs of these conditions, indicate that more systematic and scientifically based approaches are needed.[@R27] This study assesses medical care and costs of most frequently used treatments in high prevalence lumbar disorders in Korea to provide a basic standard for future usual care guidelines that may reduce health expenditures and help solve National Health Insurance deficits. This study is the first to use HIRA NPS 2011 billing data to examine and compare medical use and costs associated with most frequent lumbar disorders. To date, no studies have reported national usage data on management of most frequent lumbar disorders, and this study holds significance in that it is the first report on prevalence and treatment patterns of most frequent lumbar disorders in Korea on a national level. Such national usage data on general management of most frequent lumbar disorders captures current clinical practice patterns, and surgery rates and diagnosis-related costs provide basic information for economic evaluation and health policy and budget appropriation.

An added strength of this study is that it acts as a window onto patterns of complementary and alternative medicine (CAM) treatment for LBP in Korea, which covers such CAM treatments as acupuncture and moxibustion in National Health Insurance. Of the nLBP group, 26.4% visited Korean medicine clinics for treatment and 2.2% visited Korean medicine hospitals, resulting in an approximate rate of Korean medicine use, including acupuncture, of about 30%. Korean medicine holds various medical specialties (4 years of specialist training following 6 years of undergraduate education), of which acupuncture specialists, who specialise in acupuncture and moxibustion (13.8% of nLBP), and internal Korean Medicine specialists (14.0% of nLBP) were shown to treat LBP most frequently following conventional medicine orthopaedics (41.6% of nLBP). It is also worthy of note that Korean medicine doctors are precluded from diagnosing IDD or SS independently due to regulation restrictions in imaging device use, which may be associated with the fact that Korean medicine use for IDD and SS is much lower compared to that of nLBP.

The results show that the proportion of patients in the 50--59 age range was highest in the nLBP and IDD groups, and prevalence increased with age in the SS group. Prevalence of lumbar disc degeneration has been reported to increase with age in men and women.[@R28] Our data suggest a greater frequency of all three most common lumbar disorders in women than in men, which is consistent with reports that women present with LBP more often than men.[@R28] The reason may be partly attributed to gender role differences such as occupation, hours of work and occupational activities, including housework in addition to biological factors.

While clinics were the most frequently visited medical institution type in all three groups, the fact that Korean medicine clinics were next most frequently visited in the nLBP group is a point worthy of interest. Orthopaedics was the most frequently visited medical specialty in all three groups, followed by internal Korean medicine and acupuncture and moxibustion medicine specialties in the nLBP group. The Korean medical system is characterised by a dual, mutually exclusive medical system of conventional and Korean traditional medicine, and these circumstances are reflected in the high proportion of Korean medicine use for common lumbar disorders. These results are also concordant with survey results on the perception and usage of Korean medicine reporting LBP to be the most frequent reason for Korean medicine use (12.9%).[@R29]

The average treatment amounts per patient in inpatient and outpatient care were highest in the SS group, and long-term care hospitals had highest treatment amounts in all three groups, followed by Korean medicine hospitals and upper level general hospitals in medical institutions. Long-term care hospitals are defined as medical institutions that provide medical services by conventional medicine or Korean medicine doctors for ≥30 patients according to Korean medical law. However, long-term care hospitals are allowed more lenient standards in physician and nurse stationing than other hospitals through additional placement of social welfare workers or physiotherapists. As this study included billing data of patients with diagnoses for most common lumbar disorders in primary and four secondary diagnoses, billing data may have been inclusive of various diseases in elderly, end-term or palliative care patients, leading to higher costs in long-term care hospitals.

With regard to surgery rates, a proportion of 0.90% in the nLBP, 4.59% in the IDD and 4.85% in SS group received surgery, which, though slightly higher as data duplication may have occurred in the extraction process, is similar to Statistics Korea data. According to 2011 national statistics on major surgeries, of 1 702 638 patients who received medical care for M51 (other IDDs), 57 931 (3.40%) underwent surgery, which was the sixth most common reason for surgery, and of 1 087 162 M48 (other spondylopathies) patients, 31 077 (2.86%) received surgery, which was tallied as the 13th most common reason of all surgeries.[@R30] In the USA, the prevalence of lumbar fusion surgery has shown a 220% increase from 1990 to 2001,[@R31] and it is estimated that 250 000 laminectomies are conducted each year as of 2002.[@R32]

The most frequently used injection code in all three groups was epidural nerve block (lumbar and/or caudal), and the most frequently prescribed physiotherapy was deep heat therapy in all three groups. Non-opioid analgesic use was also similar in all three groups, with aceclofenac 100 mg used most commonly, displaying high consistency in treatment procedures, especially considering that these lumbar disorders do not share a common aetiology, severity or prognosis. This high concordance may be due to personal preference or institutional policy, and though there is the added possibility of misclassification of codes or data, as patients pay a fee for service for all healthcare services, such errors should not have occurred.

A recent report on injection treatment in Korea states that 10.8--11.5% of all patients with LBP receive injection treatment, and that this number is steadily growing. Costs of injection treatment in patients with LBP were estimated to be 15.6 billion KRW in 2006, 17 billion in 2007 and 19.1 billion in 2008, which takes up ∼3% of the total annual medical expenses for LBP.[@R18]

A 2007 US study using 5% samples of Centers for Medicare and Medicaid Services outpatient claims data from 1994 to 2001 evaluated trends and medical expenses of lumbosacral injection treatment for patients with LBP.[@R33] Participants were limited to patients aged 65 or older as the study population was from Medicare, and LBP-related lumbosacral diseases covered degenerative changes, SS, radiculopathy or sciatica, intervertebral disc displacement, osteoarthritis, spondylolisthesis and lumbosacral sprain. Considered injection treatments included epidural steroid injections, facet joint injections, sacral joint injections and current trends in fluoroscopy were also investigated. Results showed that use of epidural steroid injections increased 271% from 553 patients per 100 000 in 1994 to 2055 in 2001, and facet joint injections increased during the same period from 80 to 264. Similar trends were observed in sacral joint injections, for which codes have been used since 2000, which rose steeply from 100 in 2000 to 212 in 2001. Total Medicare costs for lumbosacral injections have increased from US\$24 million in 1994 to US\$175 million in 2001. In terms of total inflation-adjusted reimbursed costs per injection, costs rose from US\$115 in 1994 to US\$227 in 2001.

In the comparison between injection treatment recipients and non-recipients, 6876 (6.16%) of 111 544 patients with nLBP, 9546 (19.72%) of 48 413 patients with IDD and 7138 (24.75%) of 28 842 patients with SS received injection treatment. A total 1.0% in the nLBP, 7% in the IDD and 5.7% in the SS injection subgroup received surgery, which is higher in all groups than for the non-injection subgroups. The average expenditure per patient was higher in the injection compared to the non-injection subgroup in all three groups (407 083 KRW in nLBP, 615 312 KRW in IDD and 648 545 KRW in SS). This disparity in medical usage in the injection and non-injection subgroups is probably due to symptom severity, general health (including comorbidities), accessibility to healthcare and socioeconomic differences, but clinical factors could not be comprehensively analysed or adjusted for as with other studies retrospectively using claims databases.

This study used nationwide data records relating to common lumbar disorder diagnoses. However, the current disease classification system used at HIRA cannot identify pain specific to the lumbar area, and as most frequent lumbar disorders in up to four secondary diagnoses were selected in addition to the primary diagnosis in the current study, definitions of LBP and lumbar disorders relying solely on claims disease diagnosis have limited accuracy. We attempted to redeem this potential error by hypothesising that patients with LBP and lumbar disorder would require plain radiography for diagnosis and treatment, and included plain lumbar radiographs as a selection criterion, but the possibility of selection bias remains. Further consideration should be given to accurate selection in future studies using claims databases. Moreover, the accuracy of disease classification has been reported to be higher in inpatients than in outpatients, in severe disorders than in common mild disorders and in general hospital levels than in clinics.[@R34]

Though HIRA patient sample data are extracted from extensive raw data in a systematic manner, these secondary data are presented by estimate and therefore the sample size needs to be sufficiently large to establish representativeness and significance. The explanatory power of samples inevitably increases with higher frequency in inpatient populations and common disease classification, and decreases with lower frequency disease classifications. While the present study secures certain representativeness and generality as the subject matter was high prevalence lumbar disorders in Korea, weighted data of samples may still show a relatively high SD or SE.

An additional limitation of this study is that disease subcategories with distinct characteristics are presented together under single categories. For example, M511 (lumbar disorders and other IDDs with radiculopathy), which is diagnosed in cases with radiculopathy associated with lumbar IDD, takes up ∼49.11% of the IDD group. The IDD group additionally comprises such codes as M513 (other specified intervertebral disc degeneration, multiple sites in the spine; 6.02% of the IDD group) and M519 (IDD, unspecified; 10.72% of the IDD group), and considering that radiculopathy holds significant clinical relevance as a diagnosis point, lumping of different diagnosis codes into groups for analysis may be a matter of concern. Still, in the process of designing the study, physicians in current practice were in concurrence that these codes are not clearly differentiated for diagnosis in actual clinical practice settings in Korea, and analysis was performed in primary and secondary diagnoses in accordance with the opinion that various issues may be taken into account (eg, private insurance, medical care institution characteristics, individual differences in physicians) in category division and that primary and secondary diagnoses are generally used in conjunction.

Other limitations include that these results are crude presentations of current practice as socioeconomic and, as such, clinical factors influencing patterns of practice such as income, education level, residence, height, weight, mortality and health-related risk factors (eg, alcohol consumption, smoking, exercise) could not be analysed. Also, while fee-for-services for nationally covered healthcare services are comprehensively recorded in the claims database, non-reimbursable items and medicine such as over-the-counter drugs do not generate billing data. The short period additionally limited sample data analysis as determining incidence and disease duration (ie, acute, subacute, chronic stage) data by setting a washout period was not feasible. Future studies may compensate for these limitations through anonymous patient data sharing between medical institutions or governing bodies (eg, hospital medical records with personal information protected, National Health and Nutrition Examination Survey data and National Health Examination data).

Conclusions {#s5}
===========

In summary, the results of this study demonstrate distinct differences in patterns of medical care use and costs of most frequent lumbar disorders in national-level patient sample data, and should be considered in establishing guidelines for usual care in health policy and budget appropriation to provide a standard for the appropriate level of management and decision-making in common lumbar disorders in Korea.
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